2079938-92-2
Chemical Structure
JHU395
- CAS No.: 2079938-92-2
- Formula:C22H29N3O7
- Molecular Weight:447.48
IUPAC Name: isopropyl (2S)-6-diazo-5-oxo-2-(((phenyl(pivaloyloxy)methoxy)carbonyl)amino)hexanoate
InChIKey: QQIBFRQTTLIECS-KKFHFHRHSA-N
SMILES: O=C(C(C)(C)C)OC(OC(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC(C)C)=O)=O)C1=CC=CC=C1
Biological Activity: JHU395 is an orally active prodrug of 6-diazo-5-oxo-l-norleucine (HY-108357) and an antagonist of Glutamine amidotransferase. JHU395 blocks de novo purine synthesis, inhibits glutamine utilization, and induces Apoptosis. JHU395 exhibits antitumor activity. JHU395 can be used in research related to malignant peripheral nerve sheath tumors and MYC-driven medulloblastomas[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JHU395 | 99.69% | JHU395 is an orally active prodrug of 6-diazo-5-oxo-l-norleucine (HY-108357) and an antagonist of Glutamine amidotransferase. JHU395 blocks de novo purine synthesis, inhibits glutamine utilization, and induces Apoptosis. JHU395 exhibits antitumor activity. JHU395 can be used in research related to malignant peripheral nerve sheath tumors and MYC-driven medulloblastomas. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lemberg KM, et al. Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor. Molecular cancer therapeutics. 2023 Dec 01;22(12):1390-1403. [Content Brief]
- [2]. Lemberg KM, et al. The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. Molecular cancer therapeutics. 2020 Feb;19(2):397-408. [Content Brief]
- [3]. Pham K, et al. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. Journal of neuropathology and experimental neurology. 2021 Mar 22;80(4):336-344. [Content Brief]
Keywords
